Why Is Immix Biopharma $IMMX Stock Down -10.29% Today? (Find out why any stock moved today on Tickeron.) • IMMX shares fell roughly 10.29% intraday, trading near $10.29 versus a prior close of $11.47. • The primary catalyst was a dilutive $125 million underwritten common stock offering priced at $11.00 per share, below the prior session's close. • The company simultaneously reported positive interim clinical data — an 89% complete response rate for its lead CAR-T candidate NXC-201 — which was overshadowed by the financing. • The move reflects a "sell-the-news" dynamic, with profit-taking following a much-anticipated data readout compounded by share dilution. • Traders are watching offering-related supply, the final NEXICART-2 readout, and the planned BLA submission targeted for mid-2027. $IMRX $CGEM $COGT $MLYS $CMPX $CNTX $CVM